{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:40Z","timestamp":1787026600958,"version":"build-2736575974"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Triple negative breast cancer (TNBC) is the most aggressive and hard-to-treat subtype of breast cancer, affecting 10-20% of all women diagnosed with breast cancer. Surgery, chemotherapy and hormone\/Her2 targeted therapies are the cornerstones of treatment for breast cancer, but women with TNBC do not benefit from these treatments. Although the prognosis is dismal, immunotherapies hold significant promise in TNBC, even in wide spread disease because TNBC is infiltrated with more immune cells. This preclinical study is proposing to optimize an oncolytic virus-infected cell vaccine (ICV) based on a prime-boost vaccination strategy to address this unmet clinical need.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used various classes of immunomodulators to improve the immunogenicity of whole tumor cells in the prime vaccine, followed by their infection with oncolytic Vesicular Stomatitis Virus (VSVd51) to deliver the boost vaccine. For in vivo studies, we compared the efficacy of a homologous prime-boost vaccination regimen to a heterologous strategy by treating 4T1 tumor bearing BALB\/c mice and further by conducting re-challenge studies to evaluate immune memory responses in surviving mice. Due to the aggressive nature of 4T1 tumor spread (akin to stage IV TNBC in human patients), we also compared early surgical resection of primary tumors versus later surgical resection combined with vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>In vitro<\/jats:italic>\n                      results demonstrated that immunogenic cell death (ICD) markers and pro-inflammatory cytokines were released at the highest levels following treatment of mouse 4T1 TNBC cells with oxaliplatin chemotherapy and influenza vaccine. These ICD inducers also contributed towards higher dendritic cell recruitment and activation. With the top ICD inducers at hand, we observed that treatment of TNBC-bearing mice with the influenza virus-modified prime vaccine followed by VSVd51 infected boost vaccine resulted in the best survival. Furthermore, higher frequencies of both effector and central memory T cells along with a complete absence of recurrent tumors were observed in re-challenged mice. Importantly, early surgical resection combined with prime-boost vaccination led to improved overall survival in mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Taken together, this novel cancer vaccination strategy following early surgical resection could be a promising therapeutic avenue for TNBC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1098344","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:45:27Z","timestamp":1676249127000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Seyedeh-Raheleh","family":"Niavarani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"St-Cyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Gigu\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almohanad A.","family":"Alkayyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Hwa","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"32\u22129","DOI":"10.1111\/ajco.12748","article-title":"Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies","volume":"14","author":"Khosravi-Shahi","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"B2","first-page":"52\u221269","article-title":"Neoadjuvant chemotherapy considerations in triple-negative breast cancer","volume":"7","author":"McAndrew","year":"2018","journal-title":"J Target Ther Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PloS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2959\u221266","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1544\u221250","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"259\u221271","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs working group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"225\u221238","DOI":"10.1002\/cjp2.25","article-title":"Classical pathology and mutational load of breast cancer - integration of two worlds","volume":"1","author":"Budczies","year":"2015","journal-title":"J Pathol Clin Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"405\u22129","DOI":"10.1038\/nature11154","article-title":"Sequence analysis of mutations and translocations across breast cancer subtypes","volume":"486","author":"Banerji","year":"2012","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1707\u221211","DOI":"10.1001\/jamaoncol.2017.2140","article-title":"Association between genomic metrics and immune infiltration in triple-negative breast cancer","volume":"3","author":"Karn","year":"2017","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"169\u221277","DOI":"10.1007\/s12307-012-0126-7","article-title":"Tumor microenvironment and myeloid-derived suppressor cells","volume":"6","author":"Umansky","year":"2013","journal-title":"Cancer Microenviron Off J Int Cancer Microenviron Soc"},{"key":"B11","doi-asserted-by":"publisher","first-page":"151\u221267","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1785\u2212800","DOI":"10.1172\/JCI96313","article-title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","volume":"129","author":"Gruosso","year":"2019","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1070\u221280","DOI":"10.1158\/0008-5472.CAN-11-3218","article-title":"Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma","volume":"72","author":"Erdag","year":"2012","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"65\u221279","DOI":"10.1007\/978-3-319-67577-0_5","article-title":"Immunogenic and non-immunogenic cell death in the tumor microenvironment","volume":"1036","author":"Pitt","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"17\u221224","DOI":"10.1016\/j.ebiom.2018.04.020","article-title":"Lighting a fire in the tumor microenvironment using oncolytic immunotherapy","volume":"31","author":"Achard","year":"2018","journal-title":"EBioMedicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1069\u221276","DOI":"10.1007\/s00109-007-0214-1","article-title":"Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference","volume":"85","author":"Chaput","year":"2007","journal-title":"J Mol Med Berl Ger"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000465","article-title":"Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8 + T-cell functionality","volume":"8","author":"Niavarani","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"349\u221258","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the immune system: The dynamic duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00588","article-title":"Molecular and translational classifications of DAMPs in immunogenic cell death","volume":"6","author":"Garg","year":"2015","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"990\u22121000","DOI":"10.1158\/2326-6066.CIR-18-0277","article-title":"T Cell-inflamed versus non-T cell-inflamed tumors: A conceptual framework for cancer immunotherapy drug development and combination therapy selection","volume":"6","author":"Trujillo","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4312\u221221","DOI":"10.4049\/jimmunol.0901074","article-title":"Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus","volume":"183","author":"Prestwich","year":"2009","journal-title":"J Immunol Baltim Md 1950"},{"key":"B22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12916-019-1326-5","article-title":"Recent advances in triple negative breast cancer: the immunotherapy era","volume":"17","author":"Marra","year":"2019","journal-title":"BMC Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"276\u221286","DOI":"10.1053\/j.seminoncol.2012.02.007","article-title":"Whole cell vaccines\u2013past progress and future strategies","volume":"39","author":"Keenan","year":"2012","journal-title":"Semin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"211\u221221","DOI":"10.1158\/2326-6066.CIR-16-0162","article-title":"NK-cell recruitment is necessary for eradication of peritoneal carcinomatosis with an IL12-expressing maraba virus cellular vaccine","volume":"5","author":"Alkayyal","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1791\u22129","DOI":"10.1038\/mt.2012.128","article-title":"Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine","volume":"20","author":"Lemay","year":"2012","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1156\u221260","DOI":"10.4161\/hv.20740","article-title":"Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer","volume":"8","author":"Hanna","year":"2012","journal-title":"Hum Vaccines Immunother"},{"key":"B27","doi-asserted-by":"publisher","first-page":"587\u221298","DOI":"10.1007\/s00262-004-0602-0","article-title":"Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory","volume":"54","author":"Schirrmacher","year":"2005","journal-title":"Cancer Immunol Immunother CII"},{"key":"B28","doi-asserted-by":"publisher","first-page":"504\u221210","DOI":"10.1016\/j.ygyno.2016.09.018","article-title":"Phase II study of vigil\u00ae DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer","volume":"143","author":"Oh","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"97\u2212107","DOI":"10.1158\/0008-5472.CAN-12-1993","article-title":"Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells","volume":"73","author":"Tai","year":"2013","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3791\/51253","article-title":"A mouse tumor model of surgical stress to explore the mechanisms of postoperative immunosuppression and evaluate novel perioperative immunotherapies","author":"Tai","year":"2014","journal-title":"J Vis Exp JoVE"},{"key":"B31","article-title":"qPCR data analysis \u2013 unlocking the secret to successful results. PCR Troubleshooting and Optimization: The Essential Guide Caister Academic Press 2011, ISBN 978-1-904455-72-1","author":"Hellemans","year":""},{"key":"B32","doi-asserted-by":"publisher","first-page":"RESEARCH0034","DOI":"10.1016\/j.ygyno.2016.09.018","article-title":"Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes","volume":"3","author":"Vandesompele","year":"2002","journal-title":"Genome Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"44\u221259","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2460\u22127","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: Phase ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4016\u221226","DOI":"10.1200\/JCO.2003.10.005","article-title":"Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells","volume":"21","author":"Slingluff","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"679\u221286","DOI":"10.1038\/mt.2011.269","article-title":"Phase I trial of \u00ab bi-shRNAi(furin)\/GMCSF DNA\/autologous tumor cell \u00bb vaccine (FANG) in advanced cancer","volume":"20","author":"Senzer","year":"2012","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"21\u22129","DOI":"10.1159\/000360993","article-title":"Summary of bi-shRNA\/GM-CSF augmented autologous tumor cell immunotherapy (FANGTM) in advanced cancer of the liver","volume":"87","author":"Nemunaitis","year":"2014","journal-title":"Oncology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1147\u221258","DOI":"10.1158\/1078-0432.CCR-12-2733","article-title":"Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells","volume":"19","author":"Guillerme","year":"2013","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"91\u2212113","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40425-018-0398-7","article-title":"Combining surgery and immunotherapy: Turning an immunosuppressive effect into a therapeutic opportunity","volume":"6","author":"Bakos","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1119\u221228","DOI":"10.1073\/pnas.1904022116","article-title":"Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer","volume":"117","author":"Newman","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41467-019-08534-1","article-title":"Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy","volume":"10","author":"Rosato","year":"2019","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao1641","article-title":"Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy","volume":"10","author":"Bourgeois-Daigneault","year":"2018","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1098344\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:45:31Z","timestamp":1676249131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1098344\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2023.1098344"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1098344","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"article-number":"1098344"}}